Design Therapeutics, Inc. Common Stock DSGN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:55:35.386Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:54:22.386854112Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T14:55:34.889716+00:00
Design Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.30 | 413.6% | 40.8% | |||
| 25Δ | 7.78 | 384.1% | 37.0% | |||
| 30Δ | 8.27 | 354.6% | 33.1% | |||
| 35Δ | 8.76 | 325.2% | 29.3% | |||
| 40Δ | 9.25 | 295.7% | 25.4% | |||
| 45Δ | 11.95 | 231.1% | 22.4% | 9.74 | 266.2% | 21.6% |
| 50Δ | 11.32 | 212.6% | 17.4% | 10.23 | 236.7% | 17.7% |
| 55Δ | 10.72 | 207.2% | 13.8% | |||
| 60Δ | 11.20 | 177.7% | 10.0% | |||
| 65Δ | 11.69 | 148.2% | 6.1% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.30
- IV
- 413.6%
- B/E move
- 40.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.78
- IV
- 384.1%
- B/E move
- 37.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.27
- IV
- 354.6%
- B/E move
- 33.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.76
- IV
- 325.2%
- B/E move
- 29.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.25
- IV
- 295.7%
- B/E move
- 25.4%
45Δ
- Pseudo strike
- 11.95
- IV
- 231.1%
- B/E move
- 22.4%
- Pseudo strike
- 9.74
- IV
- 266.2%
- B/E move
- 21.6%
50Δ
- Pseudo strike
- 11.32
- IV
- 212.6%
- B/E move
- 17.4%
- Pseudo strike
- 10.23
- IV
- 236.7%
- B/E move
- 17.7%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.72
- IV
- 207.2%
- B/E move
- 13.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.20
- IV
- 177.7%
- B/E move
- 10.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.69
- IV
- 148.2%
- B/E move
- 6.1%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 107.97% | |
| 95.33% | |
| 116.90% | |
| 113.69% | |
| 127.00% | |
| 126.78% | |
| 123.82% | |
| 122.09% | |
| 121.93% | |
| 128.63% |
Biotechnology
DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral…
More →ELTX
Description unavailable
More →ELVN
Description unavailable
More →